Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer.
Di Yu, Head of Technical Operations and co-founder, tells more about Elicera in the film.
Register a non-binding interest to participate in Elicera's next round of financing, tentatively planned for spring 2021. We thank you for your interest and will contact you when it becomes relevant.
